Clinical trials: Docetaxel
Adenocarcinoma of the Prostate, Prostate Cancer
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
The purpose of this study is to see if the combination of chemotherapy drugs and drugs to suppress testosterone (hormone therapy) is effective in controlling early prostate cancer.
- Trial name
- NCT00165399
- Testing
- Docetaxel, Estramustine, Casodex
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer
The purpose of this study is to determine whether Paclitaxel and bevacizumab showed improved PFS compared to paclitaxel alone. Recent results of the AVADO study report a similar result for the combination of docetaxel and…
- Trial name
- TABEA (NCT01200212)
- Testing
- Taxane, Avastin, Taxane, Avastin, Xeloda
- Where
- Germany
- Volunteers
- 432 people
- Sponsor
- GBG Forschungs GmbH
Locally Advanced or Metastatic Breast Cancer
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human…
- Trial name
- NCT05296798
- Testing
- Phesgo, Giredestrant, Docetaxel
- Where
- 198 sites in United States, Argentina and 27 more
- Volunteers
- 922 people
- Sponsor
- Hoffmann-La Roche
Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
The hypothesize is that tepotinib is more effective than the investigator's choice of treatment in patients with MET-mutated NSCLC who have progressed after at least one first-line treatment.
- Trial name
- COMET (NCT06908993)
- Testing
- Tepotinib, Pemetrexed (Alimta), Vinorelbine
- Where
- 29 sites in France
- Volunteers
- 133 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Advanced Solid Tumors
Study of ABT-700 in Subjects With Advanced Solid Tumors
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-700 in subjects with advanced solid tumors that may have MET amplification or c-Met overexpression.
- Trial name
- NCT01472016
- Testing
- ABT-700, docetaxel, FOLFIRI
- Volunteers
- 74 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)
The purpose of this study is to answer the fundamental question 'The Optimal Timing of Surgery' in advanced ovarian cancer patients with different tumor burden, and to perform translational study.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT04515602
- Testing
- Primary debulking surgery, Neoadjuvant chemotherapy, PARPi
- Where
- 4 sites in China
- Volunteers
- 410 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Squamous Cell Carcinoma of the Head, Squamous Cell Carcinoma of the Neck
InductionChemo-Radio-Antibody-Treatment
This is an open-label, randomized, Phase II-study to evaluate the efficacy of a standard-TPF induction chemotherapy (IC) and an alternative TPF induction chemotherapy followed by radio-antibody-therapy, in patients with…
- Trial name
- ICRAT (NCT01181401)
- Testing
- TPF induction chemotherapy, TPF experimental, Standard Radiochemotherapy (HART)
- Where
- 5 sites in Germany
- Volunteers
- 94 people
- Sponsor
- Charite University, Berlin, Germany
HER2-Positive Breast Cancer
TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer
Both TCH (docetaxel/carboplatin/trastuzumab) and EC followed by TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab) regimens as Neoadjuvant Treatment for HER2-Positive Breast Cancer have been recommended by NCCN…
- Trial name
- neoCARH (NCT03140553)
- Testing
- TCH (docetaxel/carboplatin/trastuzumab) versus EC-TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab)
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Guangdong Provincial People's Hospital
Metastatic Breast Cancer
Docetaxel Combined With Ketoconazole in Treatment of Breast Cancer
Patients with locally advanced or metastatic breast cancer and with measurable primary breast tumor will be treated with 70mg docetaxel combined with ketoconazole.
- Trial name
- NCT00212095
- Testing
- docetaxel and ketoconazole
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- National University Hospital, Singapore
Esophageal Squamous Cell Carcinoma
SIB in Upper Thoracic Esophageal Squamous Cell Carcinoma
This study was designed to predict the toxicity and efficacy of Simultaneous Integrated Boost Intensity-modulated Chemoradiotherapy in Upper Thoracic I-IVA Esophageal Squamous Cell Carcinoma.
- Trial name
- NCT04115618
- Testing
- Simultaneous integrated boost intensity-modulated chemoradiotherapy
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Fudan University
Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
This is a multicenter, single-arm, phase II clinical study evaluating the efficacy and safety of neoadjuvant finotonlimab (anti-PD-1), cetuximab (anti-EGFR), and docetaxel in patients with resectable recurrent head and neck…
- Trial name
- BRIDGE (NCT07618624)
- Testing
- Finotonlimab, Cetuximab, Docetaxel
- Where
- 9 sites in China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer, Adenocarcinoma of the Prostate
Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy
The main purpose of this trial is to collect information and to evaluate the effects, good or bad, the combination of docetaxel and bevacizumab has on patients with high risk prostate cancer that are undergoing radical…
- Trial name
- NCT00321646
- Testing
- Bevacizumab, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Mary-Ellen Taplin, MD
Non-small Cell Lung Cancer (NSCLC)
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR…
- Trial name
- NCT06074588
- Testing
- Sacituzumab tirumotecan, Docetaxel, Pemetrexed
- Where
- 195 sites in United States, Australia and 23 more
- Volunteers
- 556 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Malignancies
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
This is a Phase I open-label, multi-center study of zamzetoclax (formerly GS-9716) tested either as monotherapy or in combination with other anti-cancer agents in patients with advanced solid malignancies.
- Trial name
- NCT05006794
- Testing
- zamzetoclax, Docetaxel, sacituzumab govitecan-hziy
- Where
- 13 sites in United States, Israel
- Volunteers
- 37 people
- Sponsor
- Gilead Sciences
Prostate Cancer
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Estramustine may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00052845
- Testing
- docetaxel, estramustine phosphate sodium, exisulind
- Where
- 80 sites in United States, Canada and 1 more
- Volunteers
- 80 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
This non-randomized, multicenter, open-label study will assess the safety and efficacy of subcutaneously administered trastuzumab in participants with early and locally advanced HER2-positive breast cancer in two sequential…
- Trial name
- SCHEARLY (NCT01940497)
- Testing
- Doxorubicin, Docetaxel, Paclitaxel
- Where
- 54 sites in Italy
- Volunteers
- 240 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
To investigate the efficacy of albumin-bound paclitaxel combined with carboplatin versus epirubicin combined with docetaxel as neoadjuvant therapy for triple-negative breast cancer.
- Trial name
- NCT04136782
- Testing
- Albumin-bound paclitaxel combined with carboplatin, Epirubicin combined with docetaxel
- Where
- 7 sites in China
- Volunteers
- 110 people
- Sponsor
- Shengjing Hospital
Squamous Cell Carcinoma of the Anus Stage III
Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.
Squamous cell carcinoma of the anus (SCCA) is a rare cancer, however its incidence is increasing worldwide. SCCA is mostly induced by human papillomavirus (HPV) infections (high-risk types such as HPV-16 and -18) and HPV-related…
- Trial name
- INTERACT-ION (NCT04719988)
- Testing
- Blood sample collection, Biopsy
- Where
- 10 sites in France
- Volunteers
- 55 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Prostate Cancer
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers
This Investigator-initiated, Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER) study will be conducted in subjects with high-risk localized or locally advanced prostate…
- Trial name
- THUNDER (NCT06282588)
- Testing
- Darolutamide, Radiotherapy, Zoladex 3.6Mg Implant
- Where
- 9 sites in Belgium
- Volunteers
- 493 people
- Sponsor
- Cancer Research Antwerp
HER2 + Breast Cancer
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer
This is a study to compare the similarity in Pharmacokinetics (PK) profile of HLX319 vs. EU-Phesgo® in patients with HER2-positive early or locally advanced breast cancer .
- Trial name
- NCT07601620
- Testing
- HLX319, EU-Phesgo®
- Volunteers
- 258 people
- Sponsor
- Shanghai Henlius Biotech